Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONNEX-2 phase III trial of iclepertin for cognitive impairment associated with schizophrenia
NL-OMON55912Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2022
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing Iclepertin once daily with Placebo once daily (2 arms). Primary endpoint: Change from baseline in MCCB overall composite T-score at Week 26. Started Apr 2022; status: completed.
02
Drugs
iclepertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NL-OMON55912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55912.